Pharmacist care and the management of coronary heart disease: A systematic review of randomized controlled trials

BMC Health Services Research

Volumn 13, Issue 1, 2013, Pages

  Cai, Hongwen ^a   Dai, Haibin ^b   Hu, Yangmin ^b   Yan, Xiaofeng ^b   Xu, Huimin ^b  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Coronary heart disease; Medication adherence; Mortality; Pharmacist; Secondary prevention

Indexed keywords

CARDIOTONIC AGENT;

CORONARY ARTERY DISEASE; HUMAN; MEDICATION COMPLIANCE; MORTALITY; PHARMACIST; PROFESSIONAL STANDARD; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

CARDIOTONIC AGENTS; CORONARY DISEASE; HUMANS; MEDICATION ADHERENCE; PHARMACISTS; PROFESSIONAL ROLE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84886733976     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-13-461     Document Type: Article

References (18)

1. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, et al. Circulation 2010 121 4 586 613 10.1161/CIRCULATIONAHA.109.192703 20089546
2. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, et al. Eur Heart J 2011 32 23 2999 3054 21873419
3. One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database. Menzin J, Wygant G, Hauch O, Jackel J, Friedman M, Curr Med Res Opin 2008 24 2 461 468 10.1185/030079908X261096 18194592 (Pubitemid 351294395)
4. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, et al. Circulation 2006 113 19 2363 2372 10.1161/CIRCULATIONAHA.106.174516 16702489 (Pubitemid 43947981)
5. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, et al. Circulation 2011 124 22 2458 2473 10.1161/CIR.0b013e318235eb4d 22052934
6. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. Rasmussen JN, Chong A, Alter DA, JAMA 2007 297 2 177 186 10.1001/jama.297.2.177 17213401 (Pubitemid 46089734)
7. Evaluation of cardiovascular morbidity associated with adherence to atorvastatin therapy. Rublee DA, Chen SY, Mardekian J, Wu N, Rao P, Boulanger L, Am J Ther 2012 19 1 24 32 10.1097/MJT.0b013e3181ee707e 20838204
8. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Gehi AK, Ali S, Na B, Whooley MA, Arch Intern Med 2007 167 16 1798 1803 10.1001/archinte.167.16. 1798 17846400 (Pubitemid 47403069)
9. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Hoffman E, Goto S, Ohman EM, Bhatt DL, Am J Med 2013 126 8 693 700 e691 10.1016/j.amjmed.2013.01.033 23800583
10. Impact of medication therapy discontinuation on mortality after myocardial infarction. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, Krumholz HM, Rumsfeld JS, Arch Intern Med 2006 166 17 1842 1847 10.1001/archinte.166.17.1842 17000940 (Pubitemid 44455166)
11. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G, Arch Intern Med 2011 171 16 1441 1453 10.1001/archinternmed.2011.399 21911628
12. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT, Arch Intern Med 2008 168 7 687 694 10.1001/archinte.168.7.687 18413550 (Pubitemid 351563951)
13. Higgins JPT, Green S, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] http://www.cochrane-handbook. org/
14. Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial. Calvert SB, Kramer JM, Anstrom KJ, Kaltenbach LA, Stafford JA, Allen LaPointe NM, Am Heart J 2012 163 4 657 665 e651 10.1016/j.ahj.2012.01.019 22520532
15. The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. Community Pharmacy Medicines Management Project Evaluation Team, Fam Pract 2007 24 2 189 200 17272285
16. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE, Pharmacotherapy 2000 20 4 410 416 10.1592/phco.20.5.410. 35048 10772372 (Pubitemid 30198847)
17. Outcomes of patients discharged from pharmacy-managed cardiovascular disease management. Olson KL, Delate T, Rasmussen J, Humphries TL, Merenich JA, Clinical Pharmacy Cardiac Risk Service Study G, Am J Manag Care 2009 15 8 497 503 19670953
18. Achieving cholesterol target in a managed care organization (ACTION) trial. Straka RJ, Taheri R, Cooper SL, Smith JC, Pharmacotherapy 2005 25 3 360 371 10.1592/phco.25.3.360.61601 15843283 (Pubitemid 40300323)